An oral nanomedicine elicits in situ vaccination effect against colorectal cancer

last updated: 2024-04-08
TitleAn oral nanomedicine elicits in situ vaccination effect against colorectal cancer
Publication TypePapers in Scientific Journals
Year of Publication2024
AuthorsZu M., Ma Y., Zhang J., Sun J., Shahbazi M. - A., Pan G., Reis R. L., Kundu S. C., Liu J., and Xiao B.

Oral administration is the most preferred approach for treating colon diseases, and in situ vaccination has emerged as a promising cancer therapeutic strategy. However, the lack of effective drug delivery platforms hampered the application of in situ vaccination strategy in oral treatment of colorectal cancer (CRC). Here, we construct an oral core–shell nanomedicine by preparing a silk fibroin-based dual sonosensitizer (chlorin e6, Ce6)- and immunoadjuvant (imiquimod, R837)-loaded nanoparticle as the core, with its surface coated with plant-extracted lipids and pluronic F127 (p127). The resultant nanomedicines (Ce6/R837@Lp127NPs) maintain stability during their passage through the gastrointestinal tract and exert improved locomotor activities under ultrasound irradiation, achieving efficient colonic mucus infiltration and specific tumor penetration. Thereafter, Ce6/R837@Lp127NPs induce immunogenic death of colorectal tumor cells by sonodynamic treatment, and the generated neoantigens in the presence of R837 serve as a potent in situ vaccine. By integrating with immune checkpoint blockades, the combined treatment modality inhibits orthotopic tumors, eradicates distant tumors, and modulates intestinal microbiota. As the first oral in situ vaccination, this work spotlights a robust oral nanoplatform for producing a personalized vaccine against CRC.

JournalACS Nano
Date Published2024-01-19
PublisherACS Publications
KeywordsColorectal cancer, immunotherapy, In situ vaccination, Mucus penetration, Nanomedicine, Oral administration
Peer reviewedyes

Back to top